Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

NCRI 2015 /
How do we assess a drug's real worth?

1st - 4th Nov 2015

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 13.11.15
Views: 1602
Rating:

Dr Antonio Fojo - National Cancer Institute, Bethesda, USA

Dr Fojo talks to ecancertv at NCRI 2015 about how the value of clinical trials and treatments can be assessed.

Since the rising cost of anticancer drugs appears inevitable, the focus has moved towards assessing the real value of a clinical trial and its outcomes, he explains.

He argues that negative data should be published by law so that unnecessary trials are not undertaken in vain.

Although his expertise are within the American system, he applauds UK body NICE on their ability to assess the scientific and financial worth of different drugs.

 

Categories:

Medicines · R&D · Regulatory · NCRI 2015

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation